| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Larry I Lipshultz | |
| Alexander W Pastuszak | |||
| Alexander J Tatem | |||
| Adithya Balasubramanian | |||
| Justin Yu | |||
| Jason Kovac | |||
| Deepankar K Sinha | |||
| Jorge Rivera-Mirabal | |||
| P2860 | cites work | CD36: implications in cardiovascular disease | Q24678338 |
| Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials | Q26822761 | ||
| Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis | Q27013801 | ||
| Ghrelin. | Q28081062 | ||
| Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency | Q28258325 | ||
| Growth hormone-releasing peptides and their analogs | Q28261803 | ||
| Effects of human growth hormone in men over 60 years old | Q28288413 | ||
| International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function | Q28289212 | ||
| Serum immunoreactive-leptin concentrations in normal-weight and obese humans | Q29617230 | ||
| Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects | Q29617231 | ||
| Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism | Q30435288 | ||
| Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies in men during experimental hypogonadal clamp | Q30435984 | ||
| Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men. | Q30438062 | ||
| Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial | Q30438239 | ||
| Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects | Q30469767 | ||
| Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies | Q30836337 | ||
| Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects | Q33565870 | ||
| Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues | Q33931979 | ||
| Testosterone and weight loss: the evidence | Q34134273 | ||
| Testosterone and metabolic syndrome: a meta-analysis study | Q34135149 | ||
| Ghrelin: structure and function | Q34406050 | ||
| The history of doping and growth hormone abuse in sport | Q34982896 | ||
| Prevalence of hypogonadism in males aged at least 45 years: the HIM study | Q35037892 | ||
| Male hypogonadism: Symptoms and treatment | Q35664659 | ||
| Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review | Q35810322 | ||
| Development of growth hormone secretagogues | Q36091061 | ||
| Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials | Q36639953 | ||
| Aging and the growth hormone/insulin like growth factor-I axis | Q36816921 | ||
| Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus | Q36891106 | ||
| Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement | Q36898845 | ||
| Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes | Q37668273 | ||
| Subclinical male hypogonadism | Q38032048 | ||
| Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach | Q38069128 | ||
| The Safety and Efficacy of Growth Hormone Secretagogues | Q39235724 | ||
| Ipamorelin, the first selective growth hormone secretagogue | Q40832148 | ||
| Growth hormone-releasing hormone stimulates mitogen-activated protein kinase | Q40877112 | ||
| Human growth hormone and human aging | Q40906146 | ||
| Growth hormone and insulin-like growth factor I treatment increase testicular luteinizing hormone receptors and steroidogenic responsiveness of growth hormone deficient dwarf mice | Q41180092 | ||
| The effect of GH-releasing peptide-2 (GHRP-2 or KP 102) on GH secretion from primary cultured ovine pituitary cells can be abolished by a specific GH-releasing factor (GRF) receptor antagonist | Q42500337 | ||
| Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor | Q42506962 | ||
| Gastrointestinal recovery after laparoscopic colectomy: results of a prospective, observational, multicenter study. | Q42630999 | ||
| Orally active growth hormone secretagogues: state of the art and clinical perspectives | Q42681045 | ||
| Aging and sex hormones in males | Q42977341 | ||
| Ghrelin enhances appetite and increases food intake in humans | Q43819888 | ||
| Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men | Q44014137 | ||
| Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss | Q44245579 | ||
| Identification of the growth‐hormone‐releasing peptide‐2 (GHRP‐2) in a nutritional supplement | Q45768168 | ||
| Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women | Q46605743 | ||
| Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. | Q47098803 | ||
| Growth hormone-releasing peptide (GHRP). | Q48303560 | ||
| Mechanisms of action of growth hormone-releasing peptide-2 in bovine pituitary cells | Q48618173 | ||
| Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. | Q51571651 | ||
| MOSH Syndrome (Male Obesity Secondary Hypogonadism): Clinical Assessment and Possible Therapeutic Approaches. | Q52317650 | ||
| Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients | Q56609522 | ||
| Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677 | Q59487805 | ||
| Effects of GHRP-2 and Hexarelin, Two Synthetic GH-Releasing Peptides, on GH, Prolactin, ACTH and Cortisol Levels in Man. Comparison with the Effects of GHRH, TRH and hCRH | Q60674335 | ||
| Obesity and Hypogonadism-A Narrative Review Highlighting the Need for High-Quality Data in Adolescents. | Q64912455 | ||
| Effects of acute intravenous injection of two growth hormone-releasing hormones (GHRH 1-40 and 1-29) on serum growth hormone and other pituitary hormones in short children with pulsatile growth hormone secretion | Q69266890 | ||
| Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men | Q73006825 | ||
| GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults | Q73074374 | ||
| Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study | Q92309509 | ||
| P433 | issue | Suppl 2 | |
| P304 | page(s) | S149-S159 | |
| P577 | publication date | 2020-03-01 | |
| P1433 | published in | Translational andrology and urology | Q27724139 |
| P1476 | title | Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males | |
| P478 | volume | 9 |
Search more.